The Cutting Edge of Medical Technology Content, Community & Collaboration
Trends to Watch in BioTech
Colleagues,
Please see links below to get up to date on key trends to watch in BioTech ...
JP Morgan Healthcare Conference ... Molecular Diagnostics Firms See Major 2010/11 Launches
As reported in GenomeWeb News ... Several molecular diagnostic firms are looking to unveil new assays and instrument systems that could greatly expand their market presence, company executives told investors at the JP Morgan Healthcare Conference held here this week.
...Qiagen,
Which currently has a molecular diagnostic assay portfolio of around 120 tests, is planning to launch new instruments over the next couple of years targeting the entire molecular diagnostics market, from point of care to high-throughput labs ...
...Cepheid,
Another firm that is looking to broaden its assay menu is Cepheid, which has been known primarily for its portfolio of HAI tests. John Bishop, the firm's CEO, told investors that the company's 2010 milestones include the clearance and launch of six tests, two of which — one for flu, and one for VanA, an antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci — have already been cleared for marketing.
... Gen-Probe,
Gen-Probe will launch its new molecular diagnostics instrument, called Panther, this year, President and CEO Carl Hull said at the conference ... The new system will target low-to-mid-volume labs. It will be fully automated, have a smaller footprint, and offer random access testing of qualitative and quantitative assays, which Hull said will enable molecular diagnostic testing capabilities not currently available on its Tigris system.
... Celera,
Celera CEO Kathy Ordonez told investors that the company ... is trying to expand the market for its KIF6 test, which tests for cardiovascular risk and statin benefit and is currently offered through Celera's Berkeley Heart Labs business. Among those efforts is a collaboration with Medco to study the ability of KIF6 testing to help in getting patients to take their statins. Earlier this week, the firm also licensed rights to the University of California, San Francisco to develop an in-house test for the gene.
... Luminex,
Luminex President and CEO Patrick Balthrop noted that the firm ... is aiming to introduce several new products in 2010, including its RVP Fast testing panel, which has been launched in Europe but will be filed for clearance in the US soon. Its test pipeline includes ag/bio and gastrointestinal panels that the firm hopes to launch in 2010.
Read on at: http://www.genomeweb.com/dxpgx/jp-morgan-healthcare-conference-mdx-...
IT to drive biotech
As reported in FierceBioTechIT ... Data processing and bioinformatics may become bottlenecks as the need grows to assemble and compare large numbers of genomes ... says Xconomist in a list of five transformational biotechnologies of the future ... In fact, four of the five technologies that made the list have a basis in computing and informatics...
Read on at: http://www.fiercebiotechit.com/story/it-drive-biotech-headway/2010-...
Personalized Medicine Payday Gets Closer
As reported in Portfolio.Com ... The nascent market for personalized medicine is on the verge of explosive growth, driven by rapid advances in genomic science and technology ...
A recent report from PricewaterhouseCoopers estimates the current market for personalized medicine at $232 billion, and projects it to grow 11 percent annually, nearly doubling to more than $450 billion by 2015 ... The personalized medicine space runs the gamut from health care IT and consumer information to understanding how variations in genetics drive individual treatment...
Read on at: http://www.portfolio.com/industry-news/health-care/2010/01/18/marke...
ENJOY!
CC
Please see links below to get up to date on key trends to watch in BioTech ...
JP Morgan Healthcare Conference ... Molecular Diagnostics Firms See Major 2010/11 Launches
As reported in GenomeWeb News ... Several molecular diagnostic firms are looking to unveil new assays and instrument systems that could greatly expand their market presence, company executives told investors at the JP Morgan Healthcare Conference held here this week.
...Qiagen,
Which currently has a molecular diagnostic assay portfolio of around 120 tests, is planning to launch new instruments over the next couple of years targeting the entire molecular diagnostics market, from point of care to high-throughput labs ...
...Cepheid,
Another firm that is looking to broaden its assay menu is Cepheid, which has been known primarily for its portfolio of HAI tests. John Bishop, the firm's CEO, told investors that the company's 2010 milestones include the clearance and launch of six tests, two of which — one for flu, and one for VanA, an antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci — have already been cleared for marketing.
... Gen-Probe,
Gen-Probe will launch its new molecular diagnostics instrument, called Panther, this year, President and CEO Carl Hull said at the conference ... The new system will target low-to-mid-volume labs. It will be fully automated, have a smaller footprint, and offer random access testing of qualitative and quantitative assays, which Hull said will enable molecular diagnostic testing capabilities not currently available on its Tigris system.
... Celera,
Celera CEO Kathy Ordonez told investors that the company ... is trying to expand the market for its KIF6 test, which tests for cardiovascular risk and statin benefit and is currently offered through Celera's Berkeley Heart Labs business. Among those efforts is a collaboration with Medco to study the ability of KIF6 testing to help in getting patients to take their statins. Earlier this week, the firm also licensed rights to the University of California, San Francisco to develop an in-house test for the gene.
... Luminex,
Luminex President and CEO Patrick Balthrop noted that the firm ... is aiming to introduce several new products in 2010, including its RVP Fast testing panel, which has been launched in Europe but will be filed for clearance in the US soon. Its test pipeline includes ag/bio and gastrointestinal panels that the firm hopes to launch in 2010.
Read on at: http://www.genomeweb.com/dxpgx/jp-morgan-healthcare-conference-mdx-...
IT to drive biotech
As reported in FierceBioTechIT ... Data processing and bioinformatics may become bottlenecks as the need grows to assemble and compare large numbers of genomes ... says Xconomist in a list of five transformational biotechnologies of the future ... In fact, four of the five technologies that made the list have a basis in computing and informatics...
Read on at: http://www.fiercebiotechit.com/story/it-drive-biotech-headway/2010-...
Personalized Medicine Payday Gets Closer
As reported in Portfolio.Com ... The nascent market for personalized medicine is on the verge of explosive growth, driven by rapid advances in genomic science and technology ...
A recent report from PricewaterhouseCoopers estimates the current market for personalized medicine at $232 billion, and projects it to grow 11 percent annually, nearly doubling to more than $450 billion by 2015 ... The personalized medicine space runs the gamut from health care IT and consumer information to understanding how variations in genetics drive individual treatment...
Read on at: http://www.portfolio.com/industry-news/health-care/2010/01/18/marke...
ENJOY!
CC
Views: 4
MedTechIQ VideoLibrary
Upcoming Events
© 2024 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
